Indoleamine 2,3‑dioxygenase suppresses humoral alloimmunity via pathways that different to those associated with its effects on T cells

  • Authors:
    • Maria Sounidaki
    • Georgios Pissas
    • Theodoros Eleftheriadis
    • Georgia Antoniadi
    • Spyridon Golfinopoulos
    • Vassilios Liakopoulos
    • Ioannis Stefanidis
  • View Affiliations

  • Published online on: May 16, 2019     https://doi.org/10.3892/br.2019.1212
  • Pages: 323-330
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic antibody‑mediated rejection remains a major cause of late graft loss. Regarding cellular alloimmunity, the immunosuppressive properties of indoleamine 2,3‑dioxygenase (IDO) have been well investigated; however, little is known of its effects on humoral alloimmunity. Therefore, the present study aimed to evaluate the effects of IDO on humoral alloimmunity. We developed a method for the induction of humoral alloimmunity in a one‑way mixed lymphocyte reaction (MLR), which was measured with an antibody‑mediated complement‑dependent cytotoxicity assay using resting cells, which are similar to the stimulator cells of the aforementioned MLR. In parallel, cellular alloimmunity was assessed in two‑way MLRs. The IDO inhibitor 1‑methyl‑DL‑tryptophan was used for evaluating the role of IDO. In order to investigate whether the pathways known to serve a role in the effects of IDO on T cells are applied in humoral alloimmunity, the general control nonderepressible‑2 (GCN‑2) kinase activator tryptophanol and the aryl hydrocarbon receptor (AhR) inhibitor CH223191 were employed. The IDO inhibitor was revealed to increased cellular autoimmunity, but was decreased by the GCN‑2 kinase activator. Unexpectedly, the AhR inhibitor decreased cellular alloimmunity. In addition, the IDO inhibitor was observed to suppress humoral alloimmunity, which may occur in manners independent of GCN‑2 kinase AhR. The present study proposed that IDO may decrease humoral alloimmunity in primary human peripheral blood mononuclear cells via pathways that differ to those associated with its effect on T cells.

Related Articles

Journal Cover

June 2019
Volume 10 Issue 6

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sounidaki, M., Pissas, G., Eleftheriadis, T., Antoniadi, G., Golfinopoulos, S., Liakopoulos, V., & Stefanidis, I. (2019). Indoleamine 2,3‑dioxygenase suppresses humoral alloimmunity via pathways that different to those associated with its effects on T cells. Biomedical Reports, 10, 323-330. https://doi.org/10.3892/br.2019.1212
MLA
Sounidaki, M., Pissas, G., Eleftheriadis, T., Antoniadi, G., Golfinopoulos, S., Liakopoulos, V., Stefanidis, I."Indoleamine 2,3‑dioxygenase suppresses humoral alloimmunity via pathways that different to those associated with its effects on T cells". Biomedical Reports 10.6 (2019): 323-330.
Chicago
Sounidaki, M., Pissas, G., Eleftheriadis, T., Antoniadi, G., Golfinopoulos, S., Liakopoulos, V., Stefanidis, I."Indoleamine 2,3‑dioxygenase suppresses humoral alloimmunity via pathways that different to those associated with its effects on T cells". Biomedical Reports 10, no. 6 (2019): 323-330. https://doi.org/10.3892/br.2019.1212